欢迎访问电脑商情在线! 请免费注册
分享到





位置:首页 > 智能终端 > 文传商讯

Prestige Biopharma Submitted Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar

作者: CN-INFO   责任编辑:文传商讯 2022-10-14 11:55:00
来源:文传商讯关键字:null

SINGAPORE -- (BUSINESS WIRE) --

Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has submitted a request to the U.S. Food and Drug Administration (FDA) for a pre-submission meeting to discuss the company’s planned Biologics License Application (BLA) for its Herceptin Biosimilar, HD201(Tuznue®).

The Biosimilar Biological Product Development (BPD) Type 4 Meeting is to discuss the format and content of a BLA in advance of the final submission. The company will discuss the overall development program of HD201 with the FDA to identify potential filing and review issues. The meeting is expected to take place around November, and the BLA submission by the end of the year.

Prestige Biopharma’s HD201 is a proposed biosimilar to Roche’s Herceptin® (trastuzumab) to be prescribed for the treatment of human epidermal growth factor 2 (HER2) positive breast and metastatic gastric cancer. Trastuzumab targets HER2, which is overexpressed in some types of cancer cells and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.

Currently, a New Drug Submission (NDS) for HD201 is under review by Health Canada and a Marketing Authorisation Application (MAA) by the Korea Ministry of Food and Drug Safety. In addition to filing a new MAA to the European Medicines Agency (EMA), the company also plans to apply for authorisation in other advanced biosimilars markets such as UK, Australia, and Singapore.

Lisa Park, CEO of Prestige Biopharma, commented: “This Type 4 Meeting will be the final gate of BLA submission for HD201. In addition to the Bridging Study on biosimilarity of HD201 to US-Herceptin® and the Biosimilar Initial Advisory Meeting with FDA in 2019, we have been through a series of meetings with the FDA on each step of the development to prepare the launch of HD201 in US to help more patients in need. We will take this final step to thoroughly review and finalise the application for FDA’s approval.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20221013006097/en/

CONTACT:

Media Inquiries
Global Communications, Prestige Biopharma
www.prestigebiopharma.com
Yujin Suh
+65-6924-6535
info@prestigebio.com

相关新闻:
网友评论(0) 评论仅代表网友个人观点,不代表CBINews观点。
CBINews网友您好,欢迎发表评论:(注册 后发表评论,可就本文发起辩论,将会获得更多关注)
 CBINews网友  注册邮箱:  

整合营销 |  CBINews刊例 |  《电脑商情报》刊例 |  联系方式 |  版权声明 |  友情链接

内容版权所有:电脑商情在线 北京米迪亚广告有限公司

地址:北京市海淀区中关村南大街28号6层 联系电话:(010)62178877-218

商务、内容合作QQ:15528356 客服电话:800-886-4689

电脑商情信息服务集团 成都华好网景科技有限公司

ICP证:川B2-20070068-5 川预审H8VZ-RBP6-X228-T60Z号 北京市公安局海淀分局备案编号:1101083710